Radiation dose estimates for [18F]5-fluorouracil derived from PET-Based and tissue-based methods in rats

Molecular Imaging and Biology

Volumn 10, Issue 6, 2008, Pages 341-348

  Kesner, Adam L ^a   Hsueh, Wei Ann ^a   Czernin, Johannes ^a   Padgett, Henry ^b   Phelps, Michael E ^a   Silverman, Daniel H S ^a  

^a UCLA MEDICAL CENTER   (United States)

^b Siemens Molecular Imaging Biomarker Research   (United States)

Author keywords

18F 5 fluorouracil; Interspecies extrapolation; Radiodosimetry; Small animal PET

Indexed keywords

FLUOROURACIL F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; EX VIVO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOASSAY; RAT; SPRAGUE DAWLEY RAT; TISSUE REACTION;

ANIMALS; FLUORINE RADIOISOTOPES; FLUOROURACIL; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

ANIMALIA; RATTUS; RODENTIA;

EID: 53549120491     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-008-0160-5     Document Type: Article

References (33)

1. Tang G, Wang M, Tang X, Luo L, Gan M (2003) Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-L-tyrosine as oncologic PET tracer. Appl Radiat Isot 58:219-225
2. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS et al (2001) Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805-1814
3. Santens P, De Vos F, Thierens H, Decoo D, Slegers G, Dierckx RA et al (1998) Biodistribution and dosimetry of carbon-11-methoxyprogabidic acid, a possible ligand for GABA-receptors in the brain. J Nucl Med 39:307-310
4. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE (2002) Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43:92-96
5. Deterding TA, Votaw JR, Wang CK, Eshima D, Eshima L, Keil R et al (2001) Biodistribution and radiation dosimetry of the dopamine transporter ligand. J Nucl Med 42:376-381
6. Kurdziel KA, Kiesewetter DO, Carson RE, Eckelman WC, Herscovitch P (2003) Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J Nucl Med 44:1330-1339
7. ICRP Publication 62: Radiological Protection in Biomedical Research. Annals of the ICRP Volume 22/3: International Commission on Radiological Protection; 1993
8. Schmidt D, Langen KJ, Herzog H, Wirths J, Holschbach M, Kiwit JC et al (1997) Whole-body kinetics and dosimetry of L-3-123I-iodo-alpha-methyltyrosine. Eur J Nucl Med 24:1162-1166
9. Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I et al (2002) Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 29:147-157
10. Palm S, Enmon RM Jr., Matei C, Kolbert KS, Xu S, Zanzonico PB et al (2003) Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: Correlative MicroPET and MRI. J Nucl Med 44:1148-1155
11. Loevinger R, Budinger T, Watson E (1988) MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York, NY
12. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R et al (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663-666
13. Shani J, Wolf W (1977) A model for prediction of chemotherapy response to 5-fluorouracil based on the differential distribution of 5-[18F]fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res 37:2306-2308
14. Bellemann ME, Brix G, Haberkorn U, Ostertag HJ, Lorenz WJ (1994) Drug-specific 19F NMR and dynamic 18F PET imaging of the cytostatic agent 5-fluorouracil. IEEE Trans Nucl Sci 41:2856-2861
15. Bading JR, Alauddin MM, Fissekis JD, Shahinian AH, Joung J, Spector T et al (2000) Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. J Nucl Med 41:1714-1724
16. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Mohler M, Oberdorfer F et al (1998) Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 39:1197-1202
17. Cristy M, Eckerman K (1987) Specific absorbed fractions of energy at various ages from internal photons sources. Oak Ridge National Laboratory, Oak Ridge, TN
18. Segars WP, Tsui BM, Frey EC, Johnson GA, Berr SS (2004) Development of a 4-D digital mouse phantom for molecular imaging research. Mol Imaging Biol 6:149-159
19. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023-1027
20. Kirschner A, Ice R, Beierwaltes W (1975) Letters to the editor. J Nucl Med 16:248-249
21. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al (1999) MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40:37S-61S
22. Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA (2003) 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 44:1482-1488
23. Mankoff DA, Peterson LM, Tewson TJ, Link JM, Gralow JR, Graham MM et al (2001) [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 42:679-684
24. Bevington P, Robinson D (1992) Data Reduction and Error Analysis for the Physical Sciences, 2nd ed. McGraw-Hill, New York, NY
25. ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals. International Commission on Radiological Protection; 1987
26. Brix G, Bellemann ME, Gerlach L, Haberkorn U (1998) Intra- and extracellular fluorouracil uptake: Assessment with contrast-enhanced metabolic F-19 MR imaging. Radiology 209:259-267
27. Brix G, Bellemann ME, Haberkorn U, Gerlach L, Bachert P, Lorenz WJ (1995) Mapping the biodistribution and catabolism of 5-fluorouracil in tumor-bearing rats by chemical-shift selective 19F MR imaging. Magn Reson Med 34:302-307
28. Kissel J, Brix G, Bellemann ME, Strauss LG, Dimitrakopoulou-Strauss A, Port R et al (1997) Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 57:3415-3423
29. Visser GW, Gorree GC, Peters GJ, Herscheid JD (1990) Tissue distribution of [18F]-5-fluorouracil in mice: Effects of route of administration, strain, tumour and dose. Cancer Chemother Pharmacol 26:205-209
30. Shani J, Young D, Schlesinger T, Siemsen JK, Chlebowski RT, Bateman JR et al (1982) Dosimetry and preliminary human studies of 18F-5-fluorouracil. Int J Nucl Med Biol 9:25-35
31. Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J et al (2006) Predicting chemotherapy response to paclitaxel with 18F-fluoropaclitaxel and PET. J Nucl Med 47:1995-1999
32. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD et al (2005) Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 46:1866-1871
33. Kesner AL, Hsueh W-A, Htet NL, Pio BS, Czernin J, Pegram MD, Phelps ME, Silverman DHS (2007) Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts. J Nucl Med 48:2021-2027; First published on November 15, 2007